Q3 2025 Holdings
Filed 2025-11-14 | 91 holdings | $13.8B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↑ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Opthea Limited | SPONSORED ADS | 68386J208 | $0 | 2,087,320 | 0.0% |
| Surrozen, Inc.(SRZNW) | W EXP 8/11/2026 | 86889P117 | $14.8K | 833,333 | 0.0% |
| Acrivon Therapeutics, Inc.(ACRV) | COMMON STOCK | 004890109 | $41.3K | 22,809 | 0.0% |
| Tyra Biosciences, Inc.(TYRA) | COM | 90240B106 | $148.4K | 10,607 | 0.0% |
| Vyne Therapeutics Inc.(VYNE) | COM | 92941V308 | $285.2K | 851,353 | 0.0% |
| Aligos Therapeutics, Inc.(ALGS) | COM | 01626L204 | $813.9K | 83,055 | 0.0% |
| Contineum Therapeutics, Inc.(CTNM) | CL A | 21217B100 | $912.6K | 77,670 | 0.0% |
| Generation Bio Co. | COM | 37148K209 | $1.2M | 194,493 | 0.0% |
| Kala BIO, Inc.(KALA) | COM | 483119202 | $1.5M | 985,093 | 0.0% |
| Tectonic Therapeutic, Inc.(TECX) | COM | 878972108 | $1.6M | 100,000 | 0.0% |
| Protara Therapeutics, Inc.(TARA) | COM STK | 74365U107 | $2.3M | 536,832 | 0.0% |
| Enliven Therapeutics, Inc.(ELVN) | COM | 29337E102 | $2.4M | 114,833 | 0.0% |
| Wave Life Sciences Ltd.(WVE) | SHS | Y95308105 | $2.5M | 344,063 | 0.0% |
| Vir Biotechnology, Inc.(VIR) | COM | 92764N102 | $3.1M | 542,539 | 0.0% |
| LB Pharmaceuticals Inc.(LBRX) | COM SHS | 50180M108 | $3.2M | 200,000 | 0.0% |
| Ventyx Biosciences, Inc.(VTYX) | COM | 92332V107 | $3.2M | 1,023,130 | 0.0% |
| vTv Therapeutics, Inc.(VTVT) | CL A | 918385204 | $3.5M | 148,314 | 0.0% |
| MBX Biosciences, Inc.(MBX) | COM | 55287L101 | $4.9M | 277,777 | 0.0% |
| TScan Therapeutics, Inc.(TCRX) | COM | 89854M101 | $5.1M | 2,784,792 | 0.0% |
| Heron Therapeutics, Inc.(HRTX) | COM | 427746102 | $5.4M | 4,251,951 | 0.0% |
| Skye Bioscience, Inc.(SKYE) | COM | 83086J200 | $5.7M | 1,450,638 | 0.0% |
| Relay Therapeutics, Inc.(RLAY) | COM | 75943R102 | $6.1M | 1,160,117 | 0.0% |
| Alumis Inc.(ALMS) | COM | 022307102 | $6.2M | 1,562,500 | 0.0% |
| Sagimet Biosciences Inc.(SGMT) | COM SER A | 786700104 | $6.5M | 952,996 | 0.0% |
| Sana Biotechnology, Inc.(SANA) | COM | 799566104 | $7.2M | 2,030,949 | 0.1% |
| Agios Pharmaceuticals, Inc.(AGIO) | COM | 00847X104 | $7.6M | 189,866 | 0.1% |
| Pharvaris N.V.(PHVS) | COM | N69605108 | $9.4M | 375,000 | 0.1% |
| Viking Therapeutics, Inc.(VKTX) | COM | 92686J106 | $9.6M | 366,083 | 0.1% |
| Crinetics Pharmaceuticals, Inc.(CRNX) | COM | 22663K107 | $11.7M | 280,000 | 0.1% |
| Sionna Therapeutics, Inc.(SION) | COM | 829401108 | $11.8M | 400,000 | 0.1% |
| Nuvalent, Inc.(NUVL) | COM | 670703107 | $12.4M | 143,937 | 0.1% |
| Design Therapeutics, Inc.(DSGN) | COM | 25056L103 | $12.9M | 1,712,882 | 0.1% |
| Xencor, Inc.(XNCR) | COM | 98401F105 | $12.9M | 1,102,106 | 0.1% |
| Taysha Gene Therapies, Inc.(TSHA) | COM SHS | 877619106 | $13.1M | 4,004,756 | 0.1% |
| CytomX Therapeutics, Inc.(CTMX) | COM | 23284F105 | $13.6M | 4,250,826 | 0.1% |
| Arcellx, Inc.(ACLX) | COMMON STOCK | 03940C100 | $13.7M | 166,825 | 0.1% |
| Prelude Therapeutics Inc.(PRLD) | COM | 74065P101 | $14.6M | 10,123,824 | 0.1% |
| DBV Technologies S.A.(DBVT) | SPONSORED ADS | 23306J309 | $14.6M | 1,461,425 | 0.1% |
| Xenon Pharmaceuticals Inc.(XENE) | COM | 98420N105 | $14.9M | 370,208 | 0.1% |
| Akero Therapeutics, Inc.(AKRO) | COM | 00973Y108 | $15.4M | 324,630 | 0.1% |
| Cerus Corporation(CERS) | COM | 157085101 | $15.9M | 10,008,345 | 0.1% |
| Spyre Therapeutics, Inc.(SYRE) | COM | 00773J202 | $16.8M | 1,000,000 | 0.1% |
| Sera Prognostics, Inc.(SERA) | CLASS A COM | 81749D107 | $16.8M | 5,498,170 | 0.1% |
| Neurogene Inc.(NGNE) | COM | 64135M105 | $17.2M | 991,691 | 0.1% |
| Celldex Therapeutics, Inc.(CLDX) | COM | 15117B202 | $17.2M | 665,370 | 0.1% |
| Cidara Therapeutics, Inc.(CDTX) | COM | 171757206 | $21.8M | 227,272 | 0.2% |
| Disc Medicine, Inc.(IRON) | COM | 254604101 | $22.3M | 337,050 | 0.2% |
| Vaxcyte, Inc.(PCVX) | COM | 92243G108 | $23.1M | 640,885 | 0.2% |
| Avidity Biosciences, Inc.(RNA) | COM | 05370A108 | $27.2M | 625,000 | 0.2% |
| argenx SE(ARGX) | SPONSORED ADR | 04016X101 | $27.9M | 37,760 | 0.2% |